MMSI

TentativeAI MemoPost-earnings T+3

Merit Medical

As of 2026-08-04/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

report lacks a dated company-specific catalyst beyond generic cadence for its sector profile; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 beat and FY2026 outlook raise • 2026-07-30

Base target: $100 / p=50% prob

Biggest risk

The market still needs to validate that growth and margin improvement persist beyond Q2, particularly as procedure seasonality and tariff uncertainty affect the second half. Year-to-date free cash flow was down 14%, and analyst-revision detail remains incomplete.

Invalidation

Break below $78 or thesis failure.

What would change my mind?

The Q2 print exceeded expectations on revenue, organic growth, margin, and EPS, while FY2026 guidance was raised. The reported analyst target median of $99.8182 implies meaningful upside from the $85.53 anchor price. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

high

As of

2026-08-04

Base target

$100

p=50%

Bull target

$105

p=30%

Bear target

$78

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Seasonality, tariffs, and guidance quality
Sustained organic growth and margin execution
The Q2 print exceeded expectations on revenue, organic growth, margin, and EPS, while FY2026 guidance was raised.

BearKey bullets

Analyst target revisions and consensus-estimate changes are not fully available.
OEM and acquisition performance can be variable quarter to quarter.
Q2 profitability included tariff-refund benefits that may not recur.

WatchKey bullets

Q2 beat and FY2026 outlook raise

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $100 (p=50%)

Target spread vs base: +5% / -22%

Scenario probabilities

Bull Target: $105 (p=30%)Base Target: $100 (p=50%)Bear Target: $78 (p=20%)

Commentary

Post-print coverage is favorable: the company confirmed a beat and raised guidance, while MarketBeat reported Q2 EPS of $1.19 versus $0.96 consensus and revenue of $418.84 million versus $405.25 million expected. The stock closed at $85.53 on August 3, up 0.61% that session. Post-print target-raise headlines are available, but cumulative reaction and full analyst revision detail remain incomplete; confidence is positive but not high-conviction. [#SEC-8K-2026-07-30]

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Seasonality, tariffs, and guidance quality
Sustained organic growth and margin execution

Scenarios

Bull Target (Scenario probability)

$105 / p=30% prob

Base Target (Scenario probability)

$100 / p=50% prob

Bear Target (Scenario probability)

$78 / p=20% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-30
Q2 beat and FY2026 outlook raise
Merit reported Q2 revenue of $418.8 million, non-GAAP EPS of $1.19, 9% organic constant-currency growth, and raised FY2026 constant-currency revenue-growth and non-GAAP EPS guidance. [#SEC-8K-2026-07-30]
Prob 100.00% • Move 7.30% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Seasonality, tariffs, and guidance quality
2026-11-02
Stored earnings context flags normal procedure seasonality, tariff uncertainty, and the risk that reported profitability benefits from refunds are not repeatable. [#PR-EARNINGS-2026-08-01]
Prob 70% • Move -6% • Priced-in 50%

Long-term Catalysts

Months to a year

Sustained organic growth and margin execution
2027-08-04
The Q2 release described improving revenue trends and profitability; maintaining that trajectory would support medium-term upside. [#SEC-8K-2026-07-30]
Prob 65% • Move 12% • Priced-in 55%

Risks

Analyst target revisions and consensus-estimate changes are not fully available.
OEM and acquisition performance can be variable quarter to quarter.
Q2 profitability included tariff-refund benefits that may not recur.
Q3 procedure seasonality may cause sequential revenue and EPS moderation.
Tariff exposure and uncertainty could pressure margins and earnings.
Year-to-date free cash flow declined 14%, limiting confidence in earnings-quality improvement.

Peers

Symbol	Summary
LIVN	Similar-sector medtech comparator with broadly comparable market capitalization; useful for operating and valuation context, though detailed peer estimates were not provided.
NVST	Similar-sector medtech comparator near MMSI's market-cap range; direct peer context is limited by the packet's lack of detailed comparative operating data.
BSX	Larger cardiovascular and interventional-device peer; relevant for category context but less comparable on scale.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

LIVN

Similar-sector medtech comparator with broadly comparable market capitalization; useful for operating and valuation context, though detailed peer estimates were not provided.

NVST

Similar-sector medtech comparator near MMSI's market-cap range; direct peer context is limited by the packet's lack of detailed comparative operating data.

BSX

Larger cardiovascular and interventional-device peer; relevant for category context but less comparable on scale.